Empagliflozine + metformine

Generic name
Empagliflozine + metformine
Brand name
ATC Code
A10BD20
Compare …

Empagliflozine + metformine

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Type 2 diabetes mellitus
  • Oral
    • ≥ 10 years

      • Empagliflozin/metforminhydrochloride: depending on the daily dose of metformin already in use: 10 mg/1700 mg per day in 2 doses or 10 mg/2000 mg in 2 doses.
        If this dosage is tolerated and stricter blood glucose regulation is needed, the dose of empagliflozin can be increased to 25 mg/day.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Hypoglycemia was the most common side effect in the empagliflozin group in children in the study.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Carefully monitor the possible effects of metformin on children's growth and puberty, as long-term data on this is lacking. No effect on growth and puberty has been observed in clinical trials lasting one year.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Biguanides
A10BA02
Sulfonylureas
A10BB01
Glucagon-like peptide-1 (GLP-1) analogues
A10BJ05
A10BJ01
A10BJ02
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK01
A10BK03

Reference

  1. Boehringer Ingelheim International GmbH, SmPC Synjardy (EU/1/15/1003/001) 15-01-2025, Rev 28, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose